Discovering Novel Antibiotic Potentiators for Gram-Negative ESKAPE Pathogens
Each year, multidrug-resistant (MDR) bacterial infections cause an estimated 700,000 deaths globally. In contrast, the approval rate for new antibiotics continues to decline or remain stagnant. Combination therapy for Gram-negative bacteria is a promising approach to replenish the development pipeline, as they can serve as de facto multitargeting therapies and circumvent resistance mechanisms to known antibiotics. In the Blainey lab, we use DropArray to identify novel antibiotic potentiators through massively parallelized screening.